Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
Authors
Keywords
-
Journal
ACTA NEUROLOGICA SCANDINAVICA
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-05-25
DOI
10.1111/ane.12963
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the Literature
- (2018) Yoshiyuki Omura et al. INTERNAL MEDICINE
- Improved treatment satisfaction after switching therapy to rituximab in relapsing–remitting MS
- (2016) Pierre de Flon et al. Multiple Sclerosis Journal
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- Improved treatment satisfaction after switching therapy to rituximab in relapsing–remitting MS
- (2016) Pierre de Flon et al. Multiple Sclerosis Journal
- The Danish Multiple Sclerosis Treatment Register
- (2016) Melinda Magyari et al. Clinical Epidemiology
- Spinal epidural abscess following treatment with rituximab
- (2015) J. D. Avila et al. ACTA NEUROLOGICA SCANDINAVICA
- The Swedish MS registry - clinical support tool and scientific resource
- (2015) J. Hillert et al. ACTA NEUROLOGICA SCANDINAVICA
- Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
- (2015) R. F. van Vollenhoven et al. JOURNAL OF RHEUMATOLOGY
- CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?
- (2014) Panagiotis Pateinakis et al. Biomed Research International
- Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
- (2011) David B. Clifford ARCHIVES OF NEUROLOGY
- Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma
- (2010) Corrado Tarella et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
- (2010) R. T. Naismith et al. NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
- (2009) K. R. Carson et al. BLOOD
- Late reactivation of resolved hepatitis B virus infection: An increasing complication post rituximab-based regimens treatment?
- (2008) Maria J. Garcia-Rodriguez et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Rituximab-Induced Hepatitis C Virus Reactivation After Spontaneous Remission in Diffuse Large B-Cell Lymphoma
- (2008) Ching-Yun Hsieh et al. JOURNAL OF CLINICAL ONCOLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started